Manjari Pandey
University of Tennessee Health Science Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Manjari Pandey.
Journal of Ovarian Research | 2016
George Yaghmour; Philippe Prouet; Eric Wiedower; Omer Jamy; Rebecca Feldman; Jason C. Chandler; Manjari Pandey; Mike G. Martin
BackgroundAs we have previously reported, small cell carcinoma of the ovary (SCCO) is a rare, aggressive form of ovarian cancer associated with poor outcomes. In an effort to identify new treatment options, we utilized comprehensive genomic profiling to assess the potential for novel therapies in SCCO.MethodsPatients with SCCO, SCCO-HT (hypercalcemic type), neuroendocrine tumors of the ovary (NET-O), and small cell carcinoma of the lung (SCLC) profiled by Caris Life Sciences between 2007–2015 were identified. Tumors were assessed with up to 21 IHC stains, in situ hybridization of cMET, EGFR, HER2 and PIK3CA, and next-generation sequencing (NGS) as well as Sanger sequencing of selected genes.ResultsForty-six patients with SCCO (10 SCCO, 18 SCCO-HT, 18 NET-O) were identified as well as 58 patients with SCLC for comparison. Patients with SCCO and SCCO-HT were younger (median 42 years [range 12–75] and 26 years [range 8–40], respectively) than patients with NET-O 62 [range 13–76] or SCLC 66 [range 36–86]. SCCO patients were more likely to be metastatic (70 %) than SCCO-HT (50 %) or NET-O (33 %) patients, but at a similar rate to SCLC patients (65 %). PD1 expression varied across tumor type with SCCO (100 %), SCCO-HT (60 %), NET-O (33 %) vs SCLC (42 %). PDL1 expression also varied with SCCO (50 %), SCCO-HT (20 %), NET-O (33 %) and SCLC (0 %). No amplifications were identified in cMET, EGFR, or HER2 and only 1 was found in PIK3CA (NET-O). Actionable mutations were rare with 1 patient with SCCO having a BRCA2 mutation and 1 patient with NET-O having a PIK3CA mutation. No other actionable mutations were identified.ConclusionsNo recurrent actionable mutations or rearrangements were identified using this platform in SCCO. IHC patterns may help guide the use of chemotherapy in these rare tumors.
Breast Cancer Research and Treatment | 2018
Brennan McCullar; Manjari Pandey; George Yaghmour; Felicia Hare; Kruti Patel; Matthew K Stein; Rebecca Feldman; Jason Claud Chandler; Michael Gary Martin
In the original publication, the sixth author name was published incorrectly as Matthew Stein. The correct author name should read as Matthew K Stein.
Journal of Clinical Oncology | 2011
Manjari Pandey; Cristina I. Truica
Anticancer Research | 2016
George Yaghmour; Manjari Pandey; Catherine Ireland; Kruti Patel; Sara Nunnery; Daniel Powell; Scott L. Baum; Eric Wiedower; Lee S. Schwartzberg; Mike G. Martin
Breast Cancer Research and Treatment | 2016
Brennan McCullar; Manjari Pandey; George Yaghmour; Felicia Hare; Kruti Patel; Matthew K Stein; Rebecca Feldman; Jason C. Chandler; Mike G. Martin
Clinical Breast Cancer | 2015
Manjari Pandey; Gregory R. Sutton; Smith Giri; Mike G. Martin
Journal of Clinical Oncology | 2018
Matthew K Stein; Mike G. Martin; Joanne Xiu; Sandeep Mittal; Surasak Phuphanich; Aaron Provenzano; Sharon K. Michelhaugh; Andrew Brenner; Deepa Suresh Subramaniam; Ashley Love Sumrall; Amy B. Heimberger; Santosh Kesari; W. Michael Korn; Manjari Pandey
Neuro-oncology | 2018
S Phuphanich; Nader Sanai; Joanne Xiu; Sandeep Mittal; Sharon K. Michelhaugh; Deepa Suresh Subramaniam; Manjari Pandey; Santosh Kesari; Amy B. Heimberger; Zoran Gatalica; W M Korn; A L Sumrall
Journal of Clinical Oncology | 2018
Jason Porter; Madison Boles; Manjari Pandey; Philippe Prouet; Felicia Hare; Syed Sameer Nasir; Henrik Zetterberg; Mike G. Martin
Neuro-oncology | 2017
Manjari Pandey; Kaitlin Qualls; Madison Michael; Jeffrey Sorenson; Brandon Baughman; Enrique W. Izaguirre; Matthew T. Ballo